TAG-72 Antibody (6D788): sc-73107

TAG-72 Antibody (6D788) is a mouse monoclonal IgG1 antibody that detects tumor-associated glycoprotein 72 (TAG-72) with broad species reactivity through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and flow cytometry (FCM). TAG-72 is a high molecular weight glycoprotein predominantly localized to the cytoplasm and cell membrane of malignant cells, playing a crucial role in tumor biology as a marker for various cancers. TAG-72 expression is notably high in approximately 80% of colorectal carcinomas, while being rarely found in normal epithelial tissues and benign conditions, making TAG-72 a valuable target for cancer diagnostics and therapeutics. TAG-72 is also significantly expressed in low-grade mucoepidermoid carcinomas, yet absent in pure squamous cell mucoepidermoid carcinomas, highlighting TAG-72′s potential as a differential marker in tumor classification. Furthermore, TAG-72 is associated with several gynecologic malignancies, including common epithelial ovarian and endometrial carcinomas, and TAG-72 expression in human prostatic adenocarcinomas has been shown to negatively correlate with the Gleason grade of differentiation, indicating TAG-72′s relevance in assessing tumor aggressiveness. Additionally, TAG-72 is expressed in the majority of gastric, esophageal, pancreatic, and non-small cell lung carcinomas, underscoring TAG-72′s broad applicability in cancer research. Anti-TAG-72 antibody (6D788) is particularly useful for purifying primary ovarian cancer cells from patient ascites, facilitating further studies on tumor biology and treatment responses.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

TAG-72 Antibody (6D788) References:

1. Construction and evaluation of the tumor imaging properties of 123I-labeled recombinant and enzymatically generated Fab fragments of the TAG-72 monoclonal antibody CC49.  |  Tang, Y., et al. 2007. Bioconjug Chem. 18: 677-84. PMID: 17361988
2. Guided selection of human antibody light chains against TAG-72 using a phage display chain shuffling approach.  |  Kim, SJ. and Hong, HJ. 2007. J Microbiol. 45: 572-7. PMID: 18176543
3. Monodispersed DOTA-PEG-conjugated anti-TAG-72 diabody has low kidney uptake and high tumor-to-blood ratios resulting in improved 64Cu PET.  |  Li, L., et al. 2010. J Nucl Med. 51: 1139-46. PMID: 20554731
4. Evaluation of TAG-72 as a serum marker in ovarian and breast carcinoma.  |  Esposito, G., et al. 1990. J Nucl Med Allied Sci. 34: 88-93. PMID: 2246676
5. Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents.  |  Sharifzadeh, Z., et al. 2013. Cancer Lett. 334: 237-44. PMID: 22902507
6. Tumor-associated antigen TAG-72: correlation of expression in primary and metastatic breast carcinoma lesions.  |  Lottich, SC., et al. 1985. Breast Cancer Res Treat. 6: 49-56. PMID: 2996665
7. Interferon alpha enhances expression of TAG-72 and carcinoembryonic antigen in patients with primary colorectal cancer.  |  Mahvi, DM., et al. 1995. Cancer Immunol Immunother. 40: 311-4. PMID: 7600563
8. Clinical value of serum TAG-72 as a tumor marker for pancreatic carcinoma. Comparison with CA 19-9.  |  Pasquali, C., et al. 1994. Int J Pancreatol. 15: 171-7. PMID: 7930777
9. The patterns of coexpression of tumor-associated antigens CA 19-9, TAG-72, and DU-PAN-2 in human pancreatic cancer.  |  Toshkov, I., et al. 1994. Int J Pancreatol. 15: 97-103. PMID: 8071575
10. Characterization of a new breast cancer-associated antigen and its relationship to MUC1 and TAG-72 antigens.  |  Harada, Y., et al. 1996. Tohoku J Exp Med. 180: 273-88. PMID: 9058511

The preferred TAG-72 antibody is TAG-72 Antibody (CC49): sc-20043.